Norwalk, CT – October 9, 2023 – LifeSpan Vision Ventures announced today an investment in LIfT Biosciences, the only biotech company in the world producing a neutrophil based cell therapy. LIfT Biosciences has developed a new type of cell-based immunotherapy called Immuno-Modulatory Alpha Neutrophils (IMANs) that are a first-in-class off-the-shelf cell therapy designed specifically for solid tumours. Their Immuno-Modulatory Alpha Neutrophils can now be made from iPSCs with CARs added, offering a highly potent and affordable mass production cell-based immunotherapy.
Andrew Worden, Founding Partner of LifeSpan Vision Ventures, stated: “Our investment in LIfT Biosciences represents our first in the field of oncology, and furthers our mission of supporting companies that develop therapeutics for age-related diseases with a high unmet need. We view IMANs as the next generation of cell therapy, and this technology has already been shown to infiltrate and destroy all tested solid tumours and powerfully recruit other immune cells inside the tumour to join the attack. We are excited to see this investment become a success as the team develops the therapy so that it can be scaled into something affordable for health systems, as well testing the platform across other, age-related disease settings.”
Alex Blyth, CEO of LIfT BioSciences commented that “It was a pleasure to have such an accomplished entrepreneur and inventor as Andrew Worden come on board with his fund. We continue to gain the support of bold successful entrepreneurs who can see that we have something incredibly special at LIfT that is going to change how cancer is treated forever.”
About LIfT Biosciences
LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil-based immunotherapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.
About LifeSpan Vision Ventures
Lifespan Vision Ventures invests in companies that develop therapeutics for the treatment of age-related disease and the extension of healthy lifespan.